Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2019 4
2020 4
2021 5
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Provan D, et al. Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812. Blood Adv. 2019. PMID: 31770441 Free PMC article.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Newland AC, Sánchez-González B, Rejtő L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, Dreier T, Ward ES, Michel M, Liebman HA, de Haard H, Leupin N, Kuter DJ. Newland AC, et al. Am J Hematol. 2020 Feb;95(2):178-187. doi: 10.1002/ajh.25680. Epub 2019 Dec 10. Am J Hematol. 2020. PMID: 31821591 Free PMC article. Clinical Trial.
Romiplostim use in pregnant women with immune thrombocytopenia.
Bussel JB, Cooper N, Lawrence T, Michel M, Vander Haar E, Wang K, Wang H, Saad H. Bussel JB, et al. Am J Hematol. 2023 Jan;98(1):31-40. doi: 10.1002/ajh.26743. Epub 2022 Oct 10. Am J Hematol. 2023. PMID: 36156812 Free PMC article.
Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, Semple JW, Arnold DM, Godeau B, Lambert MP, Bussel JB. Lee EJ, et al. Am J Hematol. 2021 May 1;96(5):534-537. doi: 10.1002/ajh.26132. Epub 2021 Mar 9. Am J Hematol. 2021. PMID: 33606296 Free PMC article. No abstract available.
SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia.
Hillier K, Rothman JA, Klaassen RJ, Neunert C, Rose MJ, Grace RF, Lambert MP. Hillier K, et al. Pediatr Blood Cancer. 2022 Jul;69(7):e29760. doi: 10.1002/pbc.29760. Epub 2022 May 13. Pediatr Blood Cancer. 2022. PMID: 35561101 Free PMC article. No abstract available.
Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
Moulis G, Germain J, Rueter M, Lafaurie M, Aroichane M, Comont T, Mahévas M, Viallard JF, Chèze S, Ebbo M, Audia S, Leclerc-Teffahi S, Sommet A, Beyne-Rauzy O, Michel M, Godeau B, Lapeyre-Mestre M; CARMEN investigators group. Moulis G, et al. Am J Hematol. 2022 Feb 1;97(2):E40-E44. doi: 10.1002/ajh.26404. Epub 2021 Dec 6. Am J Hematol. 2022. PMID: 34779031 Free PMC article. No abstract available.
13 results